Anzeige
Mehr »
Login
Dienstag, 16.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Biotech-Perle kurz vor entscheidender Meilenstein-Meldung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
67 Leser
Artikel bewerten:
(0)

Nanotechnology in Medical Applications 2017: Growth Drivers, Inhibitors & Opportunities

DUBLIN, October 13, 2017 /PRNewswire/ --

The "Nanotechnology in Medical Applications: The Global Market" report has been added to Research and Markets' offering.

Research and Markets Logo

This report discusses the implications of technology and commercial trends in the context of the current size and growth of the pharmaceutical market, both in global terms and analyzed by the most important national markets. The important technologies supporting nanomedicine are reviewed, and the nature and structure of the nanomedicine industry are discussed with profiles of the leading 60+ companies, including recent merger and acquisition (M&A) activity.

Five-year sales forecasts are provided for the national markets including the major therapeutic categories of products involved. Specific product categories quantified include diagnostics, cancer, CNS, anti-infective agents, cardiovasculars and anti-inflammatories.

The report includes:

  • An overview of the global markets for nanotechnology used in medical applications
  • Analyses of global market trends, with data from 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022
  • A review of technologies involved, in-depth analysis of applications in practice, and evaluation of future or potential applications
  • Information on many significant products in which the nano dimension has made a significant contribution to product effectiveness
  • A look at the regulatory environment, healthcare policies, demographics, and other factors that directly affect nanotechnology used in medicine
  • Analysis of the market's dynamics, specifically growth drivers, inhibitors, and opportunities
  • Coverage of strategies employed by companies specializing in nanomedicine to meet the challenges of this highly competitive market

Companies Mentioned:

  • Ablynx NV
  • Abraxis Bioscience (Celgene)
  • Aphios Corp.
  • Bioforce Nanosciences Holdings Inc.
  • Bio-Gateag
  • Calando Pharmaceuticals Inc.
  • C Sixty Inc. (Arrowhead Pharmaceuticals)
  • Elan (Alkermes Corp.)
  • Farfield Scientific (Biolin Scientific Ab)
  • Igi Laboratories (Teligent Inc.)
  • Kereos Inc.
  • Keystone Nano Inc.
  • Kleindiek Nanotechnikgmbh
  • Labopharm (Paladin Labs)
  • Liplasome Pharma Aps
  • Magforce Nanotechnologies
  • Magnamedics Gmbh
  • Microfluidics Corp.
  • MIV Therapeuticsinc.
  • Molecular Profiles (Juniper Pharma Services)
  • (20+ Others)

Key Topics Covered:

1: Introduction

2: Summary and Highlights

3: Nanomedicine

4: Markets for Nanomedicine

5: The Nanomedicine Industry

6: Appendix: Glossary

For more information about this report visit https://www.researchandmarkets.com/research/ggtqpn/nanotechnology_in

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2017 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.